The clinical value of C-reactive protein and its association with tumour location in patients undergoing curative surgery for colorectal cancer – a ScotScan collaborative study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249.
   PubMed Web of Science ®Google Scholar
• Park JH, Fuglestad AJ, Køstner AH, et al. Systemic inflammation and outcome in 2295 patients with stage I-III colorectal cancer from Scotland and Norway: first results from the ScotScan Colorectal Cancer Group. Ann Surg Oncol. 2020;27(8):2784–2794.
   PubMed Web of Science ®Google Scholar
• Thomsen M, Kersten C, Sorbye H, et al. Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. Oncotarget. 2016;7(46):75013–75022.
   PubMedGoogle Scholar
• Tuomisto AE, Mäkinen MJ, Väyrynen JP. Systemic inflammation in colorectal cancer: underlying factors, effects, and prognostic significance. World J Gastroenterol. 2019;25(31):4383–4404.
   PubMed Web of Science ®Google Scholar
• McMillan DC. The systemic inflammation-based glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–540.
   PubMed Web of Science ®Google Scholar
• Dolan RD, Lim J, McSorley ST, et al. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis. Sci Rep. 2017;7(1):16717.
   PubMed Web of Science ®Google Scholar
• Ying HQ, Liao YC, Sun F, et al. The role of Cancer-Elicited inflammatory biomarkers in predicting early recurrence within stage II-III colorectal cancer patients after curable resection. J Inflamm Res. 2021;14:115–129.
   PubMed Web of Science ®Google Scholar
• Yasui K, Shida D, Nakamura Y, et al. Postoperative, but not preoperative, inflammation-based prognostic markers are prognostic factors in stage III colorectal cancer patients. Mar. Br J Cancer. 2021;124(5):933–941.
   PubMed Web of Science ®Google Scholar
• McFadyen JD, Kiefer J, Braig D, et al. Dissociation of C-reactive protein localizes and amplifies inflammation: evidence for a direct biological role of C-reactive protein and its conformational changes. Front Immunol. 2018;9:1351–1351.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Ichikawa J, Giuroiu I, et al. C reactive protein impairs adaptive immunity in immune cells of patients with melanoma. J Immunother Cancer. 2020;8(1):e000234.
   PubMed Web of Science ®Google Scholar
• Kersten C, Louhimo J, Ålgars A, et al. Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer. Acta Oncol. 2013;52(8):1691–1698.
   PubMed Web of Science ®Google Scholar
• Køstner AH, Kersten C, Löwenmark T, et al. The prognostic role of systemic inflammation in patients undergoing resection of colorectal liver metastases: C-reactive protein (CRP) is a strong negative prognostic biomarker. J Surg Oncol. 2016;114(7):895–899.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017;3(2):211–219.
   PubMed Web of Science ®Google Scholar
• Loree JM, Pereira AAL, Lam M, et al. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin Cancer Res. 2018;24(5):1062–1072.
   PubMed Web of Science ®Google Scholar
• Boeckx N, Koukakis R, Op de Beeck K, et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol. 2017;28(8):1862–1868.
   PubMed Web of Science ®Google Scholar
• Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3(2):194–201.
   PubMed Web of Science ®Google Scholar
• Holch JW, Ricard I, Stintzing S, et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:87–98.
   PubMed Web of Science ®Google Scholar
• Patel M, McSorley ST, Park JH, et al. The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for Colon and rectal cancer. Br J Cancer. 2018;118(5):705–712.
   PubMed Web of Science ®Google Scholar
• Loughrey M, Quirke P, Shepherd N. Dataset for colorectal cancer histopathology reports. 3rd ed. London: The Royal College of Pathologist; 2014.
   Google Scholar
• Paschke S, Jafarov S, Staib L, et al. Are Colon and rectal cancer two different tumor entities? A proposal to abandon the term colorectal cancer. Int J Mol Sci. 2018;19(9):2577.
   PubMed Web of Science ®Google Scholar
• Salem ME, Weinberg BA, Xiu J, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 2017;8(49):86356–86368.
   PubMedGoogle Scholar
• Peng J, Li C, Wang F, et al. Right- and left-sided stage III Colon cancers present different prognostic outcomes of oxaliplatin-based adjuvant chemotherapy after curative resection. CMAR. 2018;10:2095–2103.
   Web of Science ®Google Scholar
• Dolan RD, McSorley ST, Park JH, et al. The prognostic value of systemic inflammation in patients undergoing surgery for Colon cancer: comparison of composite ratios and cumulative scores. Br J Cancer. 2018;119(1):40–51.
   PubMed Web of Science ®Google Scholar
• Colloca GA, Venturino A, Guarneri D. Second-generation inflammation-related scores are more effective than systemic inflammation ratios in predicting prognosis of patients with unresectable or metastatic pancreatic cancer receiving cytotoxic chemotherapy. Med Oncol. 2018;35(12):158.
   PubMed Web of Science ®Google Scholar
• McMillan DC, Elahi MM, Sattar N, et al. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer. 2001;41(1–2):64–69.
   PubMed Web of Science ®Google Scholar
• Scott HR, McMillan DC, Forrest LM, et al. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer. 2002;87(3):264–267.
   PubMed Web of Science ®Google Scholar
• Forrest LM, McMillan DC, McArdle CS, et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89(6):1028–1030.
   PubMed Web of Science ®Google Scholar
• Park JH, Ishizuka M, McSorley ST, et al. Staging the tumor and staging the host: a two Centre, two country comparison of systemic inflammatory responses of patients undergoing resection of primary operable colorectal cancer. Am J Surg. 2018;216(3):458–464.
   PubMed Web of Science ®Google Scholar
• Marsik C, Kazemi-Shirazi L, Schickbauer T, et al. C-reactive protein and all-cause mortality in a large hospital-based cohort. Clin Chem. 2008;54(2):343–349.
   PubMed Web of Science ®Google Scholar
• Mooi JK, Wirapati P, Asher R, et al. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial. Ann Oncol. 2018;29(11):2240–2246.
   PubMed Web of Science ®Google Scholar
• Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–1356.
   PubMed Web of Science ®Google Scholar
• Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662–680.
   PubMed Web of Science ®Google Scholar
• Køstner AH, Nielsen PS, Georgsen JB, et al. Systemic inflammation associates with a myeloid inflamed tumor microenvironment in primary resected colon cancer—may cold tumors simply be too hot? Front Immunol. 2021;12:716342.
   PubMed Web of Science ®Google Scholar
• Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754.
   PubMed Web of Science ®Google Scholar
• Rajab IM, Hart PC, Potempa LA. How C-reactive protein structural isoforms with distinctive bioactivities affect disease progression. Front Immunol. 2020;11:2126.
   PubMed Web of Science ®Google Scholar
• Hart PC, Rajab IM, Alebraheem M, et al. C-Reactive protein and cancer-diagnostic and therapeutic insights. Front Immunol. 2020;11:595835.
   PubMed Web of Science ®Google Scholar
• Laino AS, Woods D, Vassallo M, et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer. 2020;8(1):e000842.
   PubMed Web of Science ®Google Scholar